European approvals for Grifols' immunoglobulin therapy

10 March 2022

Barcelona, Spain-based plasma-derived medicine specialist Grifols (MCE: GRF) has secured approval in several European countries for Xembify (immune globulin subcutaneous human–klhw).

The innovative 20% subcutaneous immunoglobulin therapy has now been approved in France, Spain and the UK as an option to treat primary and select secondary immunodeficiencies.

The product can be used to treat chronic and rare genetic disorders that occur in people born with an impaired or absent immune system, as well as certain secondary immunodeficiencies, when a body’s defenses are compromised by environmental factors such as illness or malnutrition.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK